SHAREHOLDER ALERT: Faruqi & Faruqi Investigates Claims on Behalf of Investors of Tvardi Therapeutics

On November 22, 2025, the national securities law firm Faruqi & Faruqi, LLP announced that it is investigating potential claims against Tvardi Therapeutics, Inc. (NASDAQ: TVRD) on behalf of investors who suffered significant losses. According to the firm, the investigation centers on the company’s disclosure regarding its Phase 2 REVERT clinical trial for its drug candidate TTI‑101 in idiopathic pulmonary fibrosis (IPF). On October 13, 2025, Tvardi publicly revealed that preliminary data showed disappointing results—specifically, the trial did not meet its goals for safety, pharmacokinetics and exploratory efficacy such as changes in Forced Vital Capacity (FVC). The company also noted that baseline lung‑function measurements differed unfavorably between the placebo and treatment arms. In connection with this revelation, Tvardi’s share price plunged more than 80 %. Faruqi & Faruqi is encouraging any investor who purchased Tvardi stock or options and incurred losses to reach out to partner James (Josh) Wilson at 877‑247‑4292 or 212‑983‑9330 (Ext. 1310) to discuss potential legal rights. The law firm, which has offices in New York, Pennsylvania, California and Georgia, says it has recovered hundreds of millions of dollars for investors since its founding. #TvardiTherapeutics #investoralert #clinicaltrialfailures #securitieslitigation #SlimScan #GrowthStocks #CANSLIM